Download The Findit App

Share Your Posts On These Major Social Networks

Instatag Your Posts to Instagram Facebook + Twitter

News

Treatment Algorithms: Dyslipidemia in China - Statins dominate but traditional Chinese medicines play a role

dallas 6/18/2012 6:26:22 PM

Datamonitor estimates the antidyslipidemic drug-treated population at 53.2 million patients in the Chinese market, with obesity and diabetes the most common co-morbidities. Statins are the dominant treatment for high cholesterol while fibrates are more used for hypertriglyceridemia. Traditional Chinese medicines are the second most popular choice to treat hypercholesterolemia.

Features and benefits

  • Follow patient segmentation and treatment pathways for dyslipidemia in China.
  • Gain insight into the most commonly used therapies in China for pure hypercholesterolemia, pure hypertriglyceridemia, and mixed hyperlipidemia.
  • Understand prescribing trends and their affect on treatment regimens.
  • Identify unmet needs, especially within dyslipidemic sub-populations, which represent market opportunities in China.

Highlights

Not all patients are available for drug treatment due to the low diagnosis rate, low compliance rates, and therapeutic lifestyle management as the first line of treatment. Only 43% of dyslipidemia patients are reported diagnosed in China.

In China, statins dominate treatment regimens (monotherapies and combination therapies) for both pure hypercholesterolemia (82% of patients) and mixed hyperlipidemia (76% of patients).

The extremely low awareness of dyslipidemia was reflected in Datamonitor's physician survey, in which physicians put "more studies to provide evidence" and "improve patient awareness" on top of the list of unmet clinical needs.

Your key questions answered

  • Which antidyslipidemics drug classes and molecules are prescribed for each dyslipidemia subgroup in China?
  • What factors influence Chinese physician prescribing decisions?
  • What are the highest priority needs in the Chinese dyslipidemia market?
  • What co-morbidities and co-indications are prevalent in dyslipidemia patients to impact prescribing decisions? 

More News

Initiating Rare Disease Drug Discovery Projects


Released On: 9/3/2012
Views: 3436

Organic Light Emitting Diodes (OLEDs): Technologies and Global Markets


Released On: 9/3/2012
Views: 3124

2012 China Synthesis Polypeptide Drug Industry Market Research Report


Released On: 8/31/2012
Views: 3858

The Future of Coal Fired Power Generation Technologies


Released On: 8/27/2012
Views: 2958

Global and China Polyurethane Industry Chain Report, 2011-2012


Released On: 8/27/2012
Views: 2139

UK Commercial Property Insurance 2012


Released On: 8/27/2012
Views: 2832

IP Multimedia Subsystem (IMS) Solutions and Market Opportunities


Released On: 8/23/2012
Views: 2993

Personal Accident and Health Insurance in Hong Kong, Key Trends and Opportunities to 2016


Released On: 8/23/2012
Views: 2018

Graphene: Technologies, Applications and Markets: ReportsnReports


Released On: 8/21/2012
Views: 2711

Supraventricular Tachycardia (SVT) Therapeutics - Pipeline Assessment and Market Forecasts to 2019


Released On: 8/16/2012
Views: 3351

2012 Market Research Report on China Reversing Camera System Industry


Released On: 8/16/2012
Views: 1968

2012 Market Research Report on China Child Safety Seat Industry


Released On: 8/16/2012
Views: 4217

ReportsnReports: Agricultural Biotechnology: Emerging Technologies and Global Markets


Released On: 8/14/2012
Views: 2093

Clothing and footwear retail market in Russia 2012


Released On: 8/14/2012
Views: 1913

Clothing and footwear retail market in Poland 2012: ReportsnReports


Released On: 8/14/2012
Views: 1797

Cement market in CIS countries 2012


Released On: 8/13/2012
Views: 2206

Personal Accident and Health Insurance in the Netherlands, Key Trends and Opportunities to 2016


Released On: 8/13/2012
Views: 2097

U.S. Indoor Air Quality Market


Released On: 8/13/2012
Views: 1945

Load More wait